Item 7.01 Regulation FD Disclosure.

On August 5, 2021, BioVie Inc., a Nevada corporation (the "Company"), issued a press release announcing that it had initiated patient trials regarding its Phase III clinical study testing NE3107 for the treatment of Alzheimer's Disease. A copy of that press release is attached as Exhibit 99.1 to this Current Report and incorporated by reference into this Item 7.01.

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered "filed" under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits





(a) Exhibits



           Description
  99.1       Press Release dated August 5, 2021


                                      -2-

© Edgar Online, source Glimpses